Related Experiment Video

Updated: Oct 4, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K

siRNA nanohybrid systems: false hope or feasible answer in cancer management

Mohammed M Mehanna1,2, Kawthar K Abla2

  • 1Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.

Therapeutic Delivery
|February 2, 2022
PubMed

Insights

Small interference RNA (siRNA) shows promise for cancer therapy but faces delivery challenges. Nanohybrid systems are emerging to improve siRNA delivery and overcome limitations of single nanocarriers for enhanced cancer treatment.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Oncology

Background:

  • Exogenous small interference RNA (siRNA) is explored for cancer therapy due to its role in targeting cancer cell alterations.
  • Limitations in cellular uptake, encapsulation efficiency, cytotoxicity, and premature release hinder single nanocarrier efficacy for siRNA delivery.

Purpose of the Study:

  • To review nanohybrid systems designed to overcome the limitations of single nanocarriers for exogenous siRNA delivery in cancer therapy.
  • To highlight the synergistic potential of combining nanocarriers for improved cancer treatment.

Main Methods:

  • Literature review of nanohybrid systems developed for siRNA delivery.
  • Analysis of strategies to enhance cellular uptake and therapeutic efficacy of siRNA.

Main Results:

  • Nanohybrid systems demonstrate potential to synergize the advantages of multiple nanocarriers.
  • These systems aim to improve encapsulation, reduce cytotoxicity, and control siRNA release for targeted cancer therapy.

Conclusions:

  • Nanohybrid systems represent a promising approach to address the challenges of siRNA-based cancer therapeutics.
  • Further development of nanohybrid systems is crucial for advancing siRNA delivery and cancer treatment strategies.
Keywords:
cancernanocarriersnanohybrid systemssiRNAsystemic delivery

More Related Videos

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

11.9K
Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

549

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K